Asia Pacific Peripheral Embolization Coils Market Forecast to 2031 - Regional Analysis - by Type (Detachable Coil and Pushable Coil), Material (Platinum, Platinum & Hydrogel, and Platinum Tungsten Alloy), and Application (Bleedings & Trauma, Malformations

The Asia Pacific peripheral embolization coils market was valued at US$ 138.45 million in 2023 and is expected to reach US$ 204.52 million by 2031; it is estimated to register a CAGR of 5.0% from 2023 to 2031.

Expanding Range of Applications of Embolization Coils Boosts Asia Pacific Peripheral Embolization Coils Market

Companies operating in the peripheral embolization coils market constantly focus on new product launches and marketing approval, which helps them improve their sales. A few of the noteworthy developments in the peripheral embolization coils market are mentioned below. In January 2024, the National Medical Products Administration provided marketing approval for the ZYLOX Phoenix Peripheral Detachable Fibered Coil Embolization System manufactured by Zylox-Tonbridge Medical Technology Co Ltd. Peripheral vascular intervention is the most prevalent application of this embolization coil system. Embolization treatment of visceral aneurysms, endoleak management of abdominal aortic aneurysms, hemoptysis, and arteriovenous fistula are the other important clinical applications of the system, which are internationally recognized for their safety and efficacy. In April 2022, Boston Scientific Corporation received 510(k) clearance from the US Food and Drug Administration (FDA) for the EMBOLD Fibered Detachable Coil designed to block or reduce the blood flow rate in the peripheral vasculature. The newest addition to Boston Scientific's interventional oncology portfolio was designed for use in various embolization procedures, necessarily minimally invasive treatments intended to block one or more blood vessels to obstruct or reduce blood flow. The EMBOLD Fibered Detachable Coil features a single platform consisting of three coils, making it simpler for physicians to address various patient needs and anatomies. Thus, new product developments and marketing approvals are anticipated to create opportunities for growth of the peripheral embolization coils market during the forecast period.

Asia Pacific Peripheral Embolization Coils Market Overview

The Asia Pacific peripheral embolization coil market is segmented into China, India, Japan, South Korea, Australia, and Rest of Asia Pacific. Market growth in this region is ascribed to the continuously advancing healthcare infrastructure, and the significant incidence of abdominal aortic aneurysms, acute gastrointestinal bleeding (AGIB), and tumors in different European countries. According to an article published in BMC Public Health in April 2022, the disease burden of aortic aneurysms in China increased dramatically from 1990 to 2020, with greater mortality rates among men, elderly populations, and residents of western provinces. Varicose veins, a common condition, affect 30% of the Indian population, particularly women. Conditions can develop over time, resulting in complications such as bleeding, clotting, and ulceration that impact the quality of life of patients. Patients with varicose veins are highly susceptible to developing deep vein thrombosis because venous stasis and damage often result in superficial phlebitis, which can spread through perforating arteries and enter the deep venous system.

According to the National Cancer Centre of Japan, the country recorded more than 1million new tumor cases and 380,400 tumor-related deaths in 2022. Colorectal, stomach, lung, and prostate tumors are the most frequent cancers in Japan, accounting for over ~45% of all cancer cases. Prostate cancer diagnoses in Japan have increased 1.8 times in the last decade. A vast number of people are being diagnosed with cancer caused by a variety of possible risk factors, most notably population aging, and the cases of prostate cancer are surging at a rapid pace. AGIB is a common emergency condition with high morbidity and death rates. It is divided into upper gastrointestinal bleeding (UGIB) and lower gastrointestinal bleeding (LGIB), which determine the course of patient evaluation and treatment. According to the Queensland Government, in Australia, UGIB affects 50-150 individuals per 100,000 people per year, with a 6-8% fatality rate. The same source also states that there is no data is available on LGIB cases in Australia. According to an article published by NIH, in 2023, traumatic injuries ranked third among the leading causes of death in South Korea, accounting for 9.2% of the total mortality. Trauma is more common in younger people, and the cases reported in men are twice those in women. South Korea has a higher preventable in-hospital trauma fatality rate than other developed countries, which ranges from 5% to 10%.

Asia Pacific Peripheral Embolization Coils Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Peripheral Embolization Coils Market Segmentation

The Asia Pacific peripheral embolization coils market is categorized into type, material, application, and country.

Based on type, the Asia Pacific peripheral embolization coils market is bifurcated into detachable coil and pushable coil. The detachable coil segment held a larger market share in 2023.

In terms of material, the Asia Pacific peripheral embolization coils market is categorized into platinum, platinum & hydrogel, and platinum tungsten alloy. The platinum segment held the largest market share in 2023.

By application, the Asia Pacific peripheral embolization coils market is segmented into bleedings & trauma, malformations, tumours, visceral aneurysm, endoleak type II, and varicose veins. The bleedings & trauma segment held the largest market share in 2023.

Based on country, the Asia Pacific peripheral embolization coils market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific peripheral embolization coils market share in 2023.

Medtronic Plc; Penumbra, Inc.; Balt; Boston Scientific Corp; Cook Medical Holdings LLC; Wallaby Medical; Spartan Micro Inc.; ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO.; LTD.; Terumo Corp; and NeuroSafe Medical Co. Ltd. are among the leading companies operating in the Asia Pacific peripheral embolization coils market.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific peripheral embolization coils market.
Highlights key business priorities to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific peripheral embolization coils market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific peripheral embolization coils market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.